Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy

Area of Science:

• Oncology
• Immunology
• Cancer Therapeutics

Background:

• Significant advances in cancer immunotherapy and targeted therapies exist.
• Combining these approaches, particularly targeting oncogenic drivers like RAS, remains challenging.
• RAS family proteins are crucial oncogenes, with KRAS G12C inhibitors recently approved for specific lung cancers.

Purpose of the Study:

• To explore the rationale and potential benefits of combining KRAS G12C inhibitors with immunotherapies.
• To understand how oncogenic KRAS influences the tumor microenvironment and antitumor immunity.
• To identify novel strategies for combining RAS inhibition with immune checkpoint blockade.

Main Methods:

• Investigated the impact of targeted KRAS G12C inhibition on antitumor immunity.
• Examined the immunosuppressive signaling network controlled by oncogenic KRAS.
• Reviewed preclinical models and clinical trial data of KRAS G12C inhibitors combined with PD-(L)1 blockade.

Main Results:

• Targeted KRAS G12C inhibition can indirectly affect antitumor immunity without harming normal RAS function in immune cells.
• Preclinical models suggest combinatorial benefit of KRAS inhibition and immune checkpoint blockade.
• Clinical trials combining KRAS G12C inhibitors with PD-(L)1 blockade have not yet shown improved outcomes, partly due to toxicities.

Conclusions:

• Oncogenic KRAS signaling creates an immunosuppressive tumor microenvironment, presenting a rationale for immunotherapy combinations.
• Further understanding of KRAS-driven immune evasion is needed to optimize combination strategies.
• Developing novel approaches to combine RAS inhibition with immunotherapies is crucial for improving patient survival.